Related Experiment Videos
The pathophysiological consequences of somatostatin receptor internalization and resistance
Leo J Hofland1, Steven W J Lamberts
1Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands. hofland@imw3.fgg.eur.nl
Abstract:
Somatostatin receptors expressed on tumor cells form the rationale for somatostatin analog treatment of patients with somatostatin receptor-positive neuroendocrine tumors. Nevertheless, although somatostatin analogs effectively control hormonal hypersecretion by GH-secreting pituitary adenomas, islet cell tumors, and carcinoid tumors, significant differences are observed among patients with respect to the efficacy of treatment. This may be related to a differential expression of somatostatin receptor subtypes among tumors. In addition, the property of somatostatin receptor subtypes to undergo agonist-induced internalization has important consequences for visualizing, as well as for therapy, of receptor-positive tumors using radioisotope- or chemotherapeutic-compound-coupled somatostatin analogs. This review covers the pathophysiological role of somatostatin receptor subtypes in determining the efficacy of treatment of patients with somatostatin receptor-positive tumors using somatostatin analogs, as well as the preclinical and clinical consequences of agonist-induced receptor internalization for somatostatin receptor-targeted radio- and chemotherapy. Herein, the development and potential role of novel somatostatin analogs is discussed.
Insights
Somatostatin receptor subtypes influence treatment effectiveness for neuroendocrine tumors. Understanding receptor differences and internalization is key for targeted somatostatin analog therapies.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Somatostatin receptors (SSTRs) on tumors are crucial for somatostatin analog therapy in neuroendocrine tumors (NETs).
- While effective for hormonal control in various NETs, somatostatin analog efficacy varies significantly among patients.
- This variability may stem from differential expression of SSTR subtypes and their internalization properties.
Purpose of the Study:
- To review the pathophysiological role of SSTR subtypes in NET treatment efficacy.
- To discuss the consequences of agonist-induced SSTR internalization for targeted therapies.
- To explore the development and potential of novel somatostatin analogs.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of somatostatin receptor subtype expression and function.
- Evaluation of somatostatin analog internalization mechanisms.
Main Results:
- Differential SSTR subtype expression impacts somatostatin analog efficacy in NETs.
- Agonist-induced SSTR internalization affects tumor visualization and targeted therapy outcomes.
- Novel somatostatin analogs show potential for improved therapeutic strategies.
Conclusions:
- SSTR subtype expression and internalization are critical determinants of somatostatin analog therapy success in NETs.
- Targeted therapies utilizing somatostatin analogs require consideration of these receptor dynamics.
- Further research into novel analogs and understanding receptor behavior is warranted.